TW200726473A - Compositions and methods for treatment of cycle-related symptoms - Google Patents

Compositions and methods for treatment of cycle-related symptoms

Info

Publication number
TW200726473A
TW200726473A TW095122320A TW95122320A TW200726473A TW 200726473 A TW200726473 A TW 200726473A TW 095122320 A TW095122320 A TW 095122320A TW 95122320 A TW95122320 A TW 95122320A TW 200726473 A TW200726473 A TW 200726473A
Authority
TW
Taiwan
Prior art keywords
methods
cycle
compositions
treatment
related symptoms
Prior art date
Application number
TW095122320A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200726473A publication Critical patent/TW200726473A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
TW095122320A 2005-06-28 2006-06-21 Compositions and methods for treatment of cycle-related symptoms TW200726473A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69507705P 2005-06-28 2005-06-28

Publications (1)

Publication Number Publication Date
TW200726473A true TW200726473A (en) 2007-07-16

Family

ID=37440889

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095122320A TW200726473A (en) 2005-06-28 2006-06-21 Compositions and methods for treatment of cycle-related symptoms

Country Status (19)

Country Link
US (1) US20070009594A1 (zh)
EP (1) EP1896037A2 (zh)
JP (1) JP2008544989A (zh)
KR (1) KR20080017061A (zh)
CN (1) CN101252937A (zh)
AR (1) AR054525A1 (zh)
AU (1) AU2006263542A1 (zh)
BR (1) BRPI0613021A2 (zh)
CA (1) CA2612885A1 (zh)
CR (1) CR9601A (zh)
EC (1) ECSP078066A (zh)
GT (1) GT200600280A (zh)
IL (1) IL188237A0 (zh)
MX (1) MX2007016364A (zh)
NO (1) NO20080024L (zh)
PE (1) PE20070327A1 (zh)
RU (1) RU2007148080A (zh)
TW (1) TW200726473A (zh)
WO (1) WO2007002862A2 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
DE102007011486A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
US20120263784A1 (en) * 2009-10-12 2012-10-18 Lyka Labs Limited Emergency contraceptive
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
WO2012129812A1 (zh) * 2011-03-31 2012-10-04 深圳市康泰尔电子有限公司 电子香烟
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
DE102019115343A1 (de) * 2019-06-06 2020-12-10 EVESTRA GmbH Vaginalring für die hormonelle Kontrazeption

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4438139A (en) * 1979-08-14 1984-03-20 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estrogens
JPS60174716A (ja) * 1984-02-21 1985-09-09 Yamanouchi Pharmaceut Co Ltd パツチ剤
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
DE19705229C2 (de) * 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
EP2305229A1 (en) * 2001-12-05 2011-04-06 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
EP1648382A4 (en) * 2003-07-16 2009-09-16 Duramed Pharmaceuticals Inc HORMONE TREATMENT METHODS USING CONTRACEPTIVE DOSAGES WITH CONTINUOUS ADMINISTRATION OF ESTROGENES
WO2005117898A1 (en) * 2004-05-26 2005-12-15 Wyeth Compositions and methods for treatment of premenstrual dysphoric disorder

Also Published As

Publication number Publication date
IL188237A0 (en) 2008-06-05
ECSP078066A (es) 2008-01-23
KR20080017061A (ko) 2008-02-25
PE20070327A1 (es) 2007-05-04
RU2007148080A (ru) 2009-08-10
AU2006263542A1 (en) 2007-01-04
CA2612885A1 (en) 2007-01-04
EP1896037A2 (en) 2008-03-12
MX2007016364A (es) 2008-03-05
BRPI0613021A2 (pt) 2010-12-14
JP2008544989A (ja) 2008-12-11
WO2007002862A2 (en) 2007-01-04
CN101252937A (zh) 2008-08-27
CR9601A (es) 2008-05-05
US20070009594A1 (en) 2007-01-11
AR054525A1 (es) 2007-06-27
WO2007002862A3 (en) 2007-02-22
GT200600280A (es) 2007-02-26
NO20080024L (no) 2008-03-27

Similar Documents

Publication Publication Date Title
TW200726473A (en) Compositions and methods for treatment of cycle-related symptoms
TW200602063A (en) Compositions and methods for treatment of premenstrual dysphoric disorder
NZ593474A (en) Compositions and methods for treatment of celiac disease
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
MX2009007254A (es) Composiciones de tableta en tableta.
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
MX2019015200A (es) Compuestos de diarilhidantoina.
MX2010005931A (es) Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos.
MX342709B (es) Tratamiento contra el cancer.
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MY160041A (en) Compositions and methods for treating parasitic infections
MX338535B (es) Inhibidores de ibat para el tratamiento de enfermeades hepaticas.
MX2009013725A (es) Composiciones de fragmentos de tejido para el tratamiento de la incontinencia.
MX2009005724A (es) Comprimidos bicapa de estrogenos/serm y estrogenos/progestina.
HK1162502A1 (zh) 作為 抑制劑的氰基氨基喹諾酮和四唑並氨基喹諾酮
MX2010003045A (es) Composiciones de ciclosporina.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
GEP201706607B (en) Method for producing and using copolymer of sodium carboxymethyl cellulose and gossypol
TW200738611A (en) 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments
EP2029615B8 (en) A process for the preparation of an oxaliplatin
EP2124554A4 (en) COMPOSITIONS AND METHODS FOR CANCER TREATMENT
UA101177C2 (ru) Неиммуносупрессивный циклоспорин а для лечения мышечной дистрофии
MX2012015102A (es) Agentes terapeuticos 976.